Endometrial Cancer Medical Services in China

Endometrial carcinoma, a malignancy arising from the glandular epithelium of the uterine endometrium, is the most common gynecologic cancer in high-income countries and increasingly prevalent globally. Risk factors include unopposed estrogen exposure, obesity, hypertension, diabetes, nulliparity, and Lynch syndrome. Most cases are endometrioid adenocarcinomas (Type I), typically diagnosed at an early stage with favorable prognosis; less common subtypes—such as serous, clear cell, or carcinosarcoma (Type II)—are more aggressive and associated with higher recurrence rates. Diagnosis relies on endometrial biopsy or dilation and curettage, followed by comprehensive staging via MRI, PET-CT when indicated, and surgical pathology per FIGO guidelines. Primary treatment involves total hysterectomy with bilateral salpingo-oophorectomy and lymph node assessment; adjuvant therapy—including vaginal brachytherapy, external-beam radiotherapy, chemotherapy, or molecularly guided targeted agents (e.g., pembrolizumab for MSI-H tumors)—is tailored to histopathologic risk stratification.

China offers distinct advantages for international patients seeking endometrial cancer care. Leading oncology centers—such as Fudan University Shanghai Cancer Center and Sun Yat-sen University Cancer Center—combine deep expertise in gynecologic oncology with advanced capabilities in minimally invasive surgery (robotic-assisted and laparoscopic), precision radiation oncology (including MR-guided adaptive brachytherapy), and biomarker-driven systemic therapies. Five-year survival rates for early-stage disease exceed 90%, consistent with global benchmarks, while complex cases benefit from multidisciplinary tumor boards integrating pathology, radiology, medical oncology, and genetic counseling. Treatment costs in China are typically 40–60% lower than in the US or Western Europe, without compromising clinical quality or regulatory compliance—China’s NMPA-approved diagnostics and therapeutics align with international standards. As a dedicated medical tourism agency, we facilitate seamless access to these resources: coordinating appointments with certified specialists, verifying hospital credentials, providing itemized, transparent pricing in advance, arranging visa support, accommodation, and real-time bilingual assistance throughout diagnosis, treatment, and follow-up—ensuring continuity of care and informed decision-making.

Treatment Options & Itemized Cost Breakdown: Endometrial Carcinoma (Gynecologic Oncology)

Non-Surgical / Medical Management

*Indicated for early-stage (IA, low-grade), fertility-sparing candidates or medically inoperable patients.*

• •Progestin Therapy (e.g., Megestrol acetate 160 mg/day or Mirena IUD)

- Eligibility: Grade 1 endometrioid adenocarcinoma, <50 years, desire for fertility preservation, no myometrial invasion on MRI

- Monthly drug cost: $45–$95 (generic oral); Mirena IUD insertion + device: $280–$420 - Monitoring: Transvaginal ultrasound + endometrial biopsy q3 months × 2 years → $120/biopsy, $85/US - Hormone panel (E2, P, CA-125): $40/test

Surgical / Procedural Options

*Primary treatment for operable stages IA–IIIA; performed by Gynecologic Oncology team.*

• •Laparoscopic Total Hysterectomy + Bilateral Salpingo-Oophorectomy (TH+BSO) ± Staging Lymphadenectomy

- Eligibility: FIGO Stage IA–II, ECOG PS ≤2, no contraindications to pneumoperitoneum

- Procedure fee (Grade 3A hospital): $2,100–$3,400 - Preoperative workup (within 7 days): CBC, coagulation panel, renal/liver function, ECG, chest X-ray, pelvic MRI → $320 total

• •Robotic-Assisted TH+BSO + Pelvic/Para-aortic Lymph Node Dissection

- Eligibility: Stage IB–IIIA, high-risk histology (serous, clear cell), BMI ≥35, or surgeon preference

- Procedure fee: $4,800–$6,700 - Robotic system access fee: $1,100–$1,600 (included in above range)

Special/Complex Condition Management

• •Neoadjuvant Chemotherapy (Carboplatin/Paclitaxel × 3 cycles)

- Indication: Unresectable Stage IVB or bulky stage III with poor surgical candidacy

- Per cycle (infusion + drugs + monitoring): $1,350–$1,900

• •Adjuvant Radiotherapy (EBRT ± VBT)

- Indication: Stage II–III, LVSI+, or positive margins

- EBRT (25 fractions): $2,600–$3,300 - Vaginal Brachytherapy (3 fractions): $1,400–$1,950

• •PARP Inhibitor Maintenance (Olaparib)

- Indication: Advanced-stage *MSI-H/dMMR* or *POLE*-mutated tumors post-chemo

- Monthly supply (300 mg BID): $1,850–$2,200

Quick Selection Guide

• •<45 years, Stage IA, fertility desired: Progestin therapy + Mirena ($325 initial + $160/mo monitoring)
• •55–75 years, Stage IB, no comorbidities: Laparoscopic TH+BSO ($2,420 total with pre-op workup)
• •≥75 years or severe COPD/CHF: Palliative radiotherapy alone ($2,600–$3,300)
• •Stage IIIA, serous histology: Robotic staging + adjuvant chemo ($6,700 + $4,050 for 3 cycles)
• •Stage IVB, dMMR-positive: Carbel × 3 → olaparib maintenance ($5,400 + $5,550 for 3 months)